Plain-English translation of NCT06840977 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a retrospective study—meaning researchers review past medical records—that examines how older patients (age 70 and over) responded to a combination of chemotherapy drugs paired with targeted antibody medications like bevacizumab, panitumumab, or cetuximab for advanced colon cancer. The study wants to understand whether using reduced or standard doses of chemotherapy alongside these antibody treatments works well and is safe for elderly patients who may be more fragile.
Treatment for advanced colon cancer in older adults is tricky because standard full-dose chemotherapy can cause serious side effects in this population. This study looks at whether using lower or adjusted doses of chemotherapy combined with targeted antibodies can be just as effective while being safer and better tolerated.
You likely qualify if…
You likely don't qualify if…
This is a retrospective study, so you would not receive new treatment or make repeated visits. Instead, researchers would ask for permission to review your existing medical records—including information about the chemotherapy and antibody medications you received, your response to treatment, and any side effects you experienced. This helps doctors understand what treatment strategies work best for older patients with advanced colon cancer.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
Italy
Sponsor
Matteo Clavarezza
Enrollment target
~51 participants
Started
July 2026
Primary completion
June 2027
Age range
70 Years – 99 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Matteo Clavarezza
E.O. Ospedali Galliera
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.